Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)

3 Months Ended

Mar. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value

The following table presents the changes in the development derivative liability from inception on February 12, 2021 to March 31, 2021:

	Three Months Ended March 31, 2021
Fair value at inception on February 12, 2021	$	—
Non-cash research and development expense	2,248
Cash receipts from SFJ	750
Change in the fair value of development derivative liability	1,599
Fair value at March 31, 2021	$	4,597